AABB's donor hemovigilance efforts focus primarily on education, collaboration with other international organizations, and projects undertaken by the AABB Donor Hemovigilance Working Group.
A sub-group of the AABB Donor Hemovigilance Working Group is conducting a multi-center study to evaluate the return rate of first time COVID-19 convalescent plasma (CCP) donors.
A sub-group of the AABB Donor Hemovigilance Working Group conducted a multi-center study in 2020 to evaluate the safety of COVID-19 convalescent plasma (CCP) donation and determine whether CCP donors are at increased risk of donor adverse events (DAE) compared with conventional plasma donors.
Please check the resource section to access the publication.
The Severity Grading Tool for Donor Adverse Events was developed and validated by a sub-group of the AABB Donor Hemovigilance Working Group. Results of the formal validation study have been published (Transfusion, 2020).
The Severity Grading Tool for Donor Adverse Events was developed to enhance objective assignment of Donor Adverse Events (DAE) severity. The tool is designed to be used with the Standard for Surveillance of Complications Related to Blood Donation by ISBT/AABB/IHN. The tool aims to avoid terms such as mild, moderate and severe. It is patterned after an established clinical severity scale, Common Terminology Criteria for Adverse Events (CTCAE1) v 5.0, which rates severity by Grades 1-5 with 1 through 5 being roughly associated with mild, moderate, severe, life-threatening and death; reactions of Grade 3 or higher would be classed as "serious" in donor adverse event reporting systems.
Hemovigilance@aabb.org or +1.301.215.6588.